

Gene Expression Profiling

Last Review Date: March 8, 2019

Number: MG.MM.LA.13q

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to Health Insurance Plan of Greater New York and Group Health Incorporated, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Gene expression profiling (GEP) is a technology for identifying the genes that are active in a given sample of cells or tissue. This technique enables profiling of genes that are differentially expressed in disease states; thereby providing diagnostic and prognostic information.

Note: This guideline includes gene expression analysis, gene sequencing, and other techniques.

Related Medical Guidelines

[Analysis of KRAS Status](#)

[Epidermal Growth Factor Receptor Mutation Analysis for Patients with Non-Small-Cell Lung Cancer](#)

[BRAF Mutation Analysis](#)

[BRCA 1 and 2 Genetic Testing \(Sequence Analysis/Rearrangement\)](#)

[Carrier Screening for Parents or Prospective Parents](#)

[Chromosomal Microarray Analysis \(CMA\)](#)

[Gene Expression Profiling and Biomarker Testing for Breast Cancer](#)

[Gene Expression Testing for Multiple Myeloma](#)

[Genetic Analysis of PIK3CA Status in Tumor Cells](#)

[Genetic Counseling and Testing](#)

[Genetic Testing for Alzheimer's disease](#)

[Genetic Testing for Cancer Susceptibility](#)

[Genetic Testing for Colorectal Cancer/Lynch Syndrome](#)

[Genetic Testing for Frontotemporal Dementia \(FTD\)](#)

[Genetic Testing for Hereditary Cardiomyopathy](#)

[Genetic Testing for Hereditary Pancreatitis](#)

[Genetic Testing for PTEN Hamartoma Tumor Syndrome](#)

[Genetic Testing for Statin-Induced Myopathy](#)

[MYvantage® Hereditary Comprehensive Cancer Panel](#)

Guideline

Members are eligible for GEP testing as follows:

- I. Advanced cancer; next generation sequencing (NGS), when performed with a diagnostic lab test that has received FDA approval or clearance (e.g., Foundation One CDx)

Covered for [Medicare](#) members only when the following criteria are met:

1. Member has
 - i. either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and
 - ii. either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and
 - iii. decided to seek further cancer treatment (e.g., therapeutic chemotherapy)
 2. The diagnostic laboratory test using NGS must have:
 - i. FDA approval or clearance as a companion in vitro diagnostic; and
 - ii. an FDA approved or cleared indication for use in that patient's cancer; and
 - iii. results provided to the treating physician for management of the patient using a report template to specify treatment options
- II. Breast cancer, clinical management ; one of the following
(See EmblemHealth [Gene Expression Profiling and Biomarker Testing for Breast Cancer](#) Medical Guideline)
 1. Breast Cancer Index®
 2. EndoPredict®
 3. HerMark® (Covered for Medicare members only)
 4. MammaPrint®
 5. Oncotype DCIS (Covered for Medicare members only)
 6. Oncotype DX®
 7. Prosigna® Breast Cancer Prognostic Gene Signature Assay
- III. Non-small cell lung cancer (NSCLC) — limited [Medicare](#) coverage of Guardant360® (Guardant Health, Redwood City, CA), a plasma-based comprehensive somatic genomic profiling test (hereafter called CGP) for members with Stage IIIB/IV NSCLC when either of the following criteria are met:
 1. At diagnosis — untreated member
 - i. When results for EGFR single nucleotide variants (SNVs) and (insertions and deletions (indels); rearrangements in ALK and ROS1; and SNVs for BRAF are not available **AND** when tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated)
 2. At progression — treated member
 - i. For members progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels; rearrangements in ALK and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP from original biopsy); OR
 - ii. For patients progressing on any tyrosine kinase inhibitors (TKIs).

If no genetic alteration is detected by Guardant360, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered.

- IV. AlloMap testing for post-heart-transplant rejection (MCG Criteria # ACG: A-0623 [AC])
- V. Prostate cancer
 - 1. Decipher® Prostate is covered for all lines of business using criteria from [LCD: Decipher® Prostate Cancer Classifier Assay](#)
 - 2. Oncotype DX is covered for all lines of business using criteria from [LCD: Oncotype DX® Prostate Cancer Assay](#)
 - 3. Prolaris® Prostate Cancer is covered for all lines of business using criteria from [LCD: Prolaris™ Prostate Cancer Genomic Assay](#) for Men with Favorable Intermediate Risk Disease
 - 4. ProMark® Protemomic Prognostic Test is covered for all lines of business using criteria from [LCD: ProMark Risk Score](#)
- VI. Thyroid lesions with indeterminate cytology; one-time testing
 - 1. Afirma Thyroid FNA Analysis®
 - 2. ThyGenX (formerly miRInform®)
 - 3. ThyraMIR Thyroid miRNA classifier
 - 4. ThyroSeq next generation sequencing
- VII. Uveal melanoma (DecisionDx covered for [Medicare](#) members only)

Limitations/Exclusions

- I. Gene expression profiling is not considered medically necessary in the absence of the following:
 - 1. Analytical/clinical validity
 - 2. Clinical utility (i.e., result does not impact medical management; e.g., surgery, change in surveillance, chemotherapy, hormonal manipulation, etc.)
- II. Confirmation of consumer-based testing (including, but not limited to Health + Ancestry [23andMe] has not been shown to be of clinical value and remains experimental/investigational. Testing will be approved only for members who otherwise meet the clinical criteria in these policies
- III. Whole exome sequencing and whole genome sequencing are not considered medically necessary due to insufficient evidence of therapeutic value for all indications, including but not limited to:
 - 1. Diagnosis in members with suspected genetic disorders
 - 2. Population-based screening
 - 3. Cancer testing to identify targeted therapies
 - 4. Preimplantation genetic diagnosis and screening
 - 5. Invasive prenatal (fetal) testing
 - 6. Products of conception and pregnancy loss
 - 7. Testing for chromosomal rearrangements
- IV. The following GEP tests are not considered medically necessary due to insufficient evidence of therapeutic value (list not all-inclusive; note exceptions):
 - 1. 23-Gene NGS Pyruvate Metabolism and Related Disorders Panel
 - 2. 23andMe Health + Ancestry Service
 - 3. ADmark® Alzheimer's Evaluation
 - 4. Albinism Panel

5. AmHPR Helicobacter Pylori Antibiotic Resistance NGS Panel
6. Autosomal Dominant and Recessive Polycystic Kidney Disease Nextgen Sequencing (NGS) Panel
7. Avise tests
 - i. Avise® CTD
 - ii. Avise® MTX (aka Avise PG) (Covered for [Medicare](#) members only)
 - iii. Avise® Lupus
8. bioTheranostics Cancer TYPE ID (Covered for [Medicare](#) members only)
9. BRCAPlus
10. BluePrint®
11. BreastNext™
12. BreastOncPx™
13. BreastPRS
14. BREVAGen/BREVAGenplus
15. CancerNext, CancerNext-Expanded™
16. CancerTYPE ID® (Covered for [Medicare](#) members only)
17. Carbohydrate Metabolism Deficiency NextGen DNA Screening Panel
18. Cardiovascular Health Panel
19. CGD Universal Test Panel
20. Ciliopathies: Sequencing Panel
21. Ciliopathy NextGen Sequencing (NGS) Panel
22. Clonoseq® (Covered for [Medicare](#) members only)
23. ColoNext™
24. ColoVantage
25. Combined Cardiac Panel (Covered for [Medicare](#) members only)
26. Complete Hereditary Spastic Paraplegia Evaluation Panel
27. Complete Lung
28. Comprehensive Dystonia NextGen DNA Screening Panel
29. Comprehensive Inherited Retinal Dystrophies Sequencing Panel
30. Comprehensive Molecular Genetic Panel
Comprehensive Muscular Dystrophy/Myopathy Next Generation DNA Sequencing Panel
31. Comprehensive Molecular Genetic Panel
32. ConfirmMDx™ (Covered for [Medicare](#) members only)
33. Congenital Myopathy NextGen Sequencing (NGS) Panel
34. Congenital Stationary Night Blindness panel
35. Connective Tissue NGS Panel
36. Corus® CAD (Coverage rescinded for Medicare members effective Dec. 12, 2018 based on [noncoverage Local Coverage Determination: MoIDX: Corus® CAD Assay](#))
37. Counsyl Foresight Carrier Screen
38. Craniosynostosis next generation sequencing (NGS) panel
39. DecisionDx tests
 - i. Glioblastoma
 - ii. Uveal melanoma (Covered for [Medicare](#) members only)
40. DecodEX Microbial Genetic Identification
41. Distal Hereditary Motor Neuropathy NextGen Sequencing (NGS) Panel
42. Ehlers-Danlos Syndrome NGS Panel Dominant and Recessive
43. ENGAUGE™-cancer-DLBCL
44. Epi proColon
45. ExomeNext
46. ExomeNext-Rapid

47. Expanded Pan-Ethnic Panel
48. Familial Hemiplegic Migraine NextGen Sequencing (NGS) Panel Fetal Akinesia Deformation Sequence/Lethal Multiple Pterygium Syndrome NextGen Sequencing (NGS) Panel
49. FoundationOne CDx (Covered for [Medicare](#) members only)
50. GeneAware
51. GeneFx[®] Colon
52. GeneFx[®] Lung
53. GeneKey
54. GeneStrat[™]
55. GeneSight (Covered for [Medicare](#) members only)
56. GeneTrails[®] Solid Tumor Panel
57. GPS Cancer
58. Guardant 360[®] Panel (Covered for [Medicare](#) members only)
59. Healthy Weight DNA Insight
60. Healthy Woman DNA Insight
61. HCMNext
62. H/I Gene Expression Ratio
63. Hemophagocytic Lymphohistiocytosis Panel by next generation sequencing (NGS)
64. Hereditary Spherocytosis/Elliptocytosis NextGen Sequencing Panel
65. HERmark (Covered for [Medicare](#) members only)
66. HLA-DQB1*06:02 typing for the diagnosis or management of narcolepsy
67. HOX13:IL17BR
68. Hypokalemic and Hyperkalemic Periodic Paralysis Disorders NGS Sequencing Panel
69. Insight[®] DX Breast Cancer Profile
70. Intellectual Disability (IDNEXT) Panel
71. Leukoencephalopathy NGS Panel
72. Lipodystrophy NGS Panel
73. LUNGSEQ[®] Panel
74. Macula Risk PGx
75. Macular Degeneration Mutation Analysis
76. Mammastatin
77. miReview[®]
78. Mammostrat
79. Melaris[®]
80. Molecular Intelligence
81. My5-FU[™] (previously OnDose[™])
82. Myeloid Molecular Profile
83. myPath[®]
84. MyPRS[®] Myeloma Prognostic Risk Signature
85. myRisk[™]
86. Neurotransmitter Metabolism Deficiency NextGen DNA Screening Panel
87. Next Gen RASopathy Panel
88. Next Generation Sequencing Panel for ASXL1, RECQL4, RNU4ATAC, SOX2
89. NextStepDx PLUS[®]
90. NGS Epilepsy/Seizure Panel
91. NGS RASopathy Panel
92. OmniSeq Comprehensive
93. Oncotype DX[®] tests
 - i. AR-V7 Nucleus (Covered for [Medicare](#) members only)

- ii. Breast DCIS (Covered for [Medicare](#) members only)
- iii. Colon cancer (Covered for [Medicare](#) members only)
- 94. Oncofocus®
- 95. OnkoMatch™
- 96. OncoVantage™
- 97. Oncovue
- 98. OPA 1 gene sequencing for autosomal dominant optic atrophy and/or optic neuropathy
- 99. Osteogenesis Imperfecta NGS Panel-Recessive
- 100. OvaNext™
- 101. Overa (aka OVA1 Next Generation or second-generation Multivariate Index Assay [MIA2G] test)
- 102. PAM50 Breast Cancer Intrinsic Classifier™
- 103. PancNext™
- 104. PancaGEN (previously Pathfinder TG®) ([Medicare](#) only)
- 105. Panexia®
- 106. Paradigm Cancer Diagnostics [PCDx] Test
- 107. Pediatric Neurology Region of Interest Trio
- 108. Percepta Bronchial Genomic Classifier (Covered for [Medicare](#) members only)
- 109. Pervenio™ Lung NGS (Covered for [Medicare](#) members only)
- 110. Pontocerebellar Hypoplasia Panel
- 111. Post-Op Px™ (formerly the Prostate Px Plus)
- 112. Preparent Global Panel
- 113. Previstage™
- 114. Progenity CFnxt
- 115. Progenity® Pan-Ethnic Carrier Screening Panel
- 116. PROGENSA® PCA3 (Covered for [Medicare](#) members only)
- 117. ProOnc TumorSource DX
- 118. Provee profile panels (e.g., Opioid Risk Panel)
- 119. ProstateNext
- 120. RenalNext™
- 121. ResponseDX Tissue Origin Test Rotterdam/Veridex ([Medicare](#) only)
- 122. RetnaGene AMD
- 123. Rotterdam Signature
- 124. Saethre-Chotzen Syndrome (TWIST) Sequencing and MLPA ([Greenwood Genetic Center](#))
- 125. ScolioScore™ AIS Prognostic Test
- 126. SelectMDx for prostate cancer
- 127. Spastic Paraplegia Next Generation Sequencing Panel
- 128. Stickler Syndrome NGS Panel
- 129. SymGene68™ Next Generation Sequencing Cancer Panel
- 130. SYMPHONY™ Genomic Breast Cancer Profile (combines BluePrint, MammaPrint and TargetPrint tests)
- 131. Skeletal Dysplasia Ciliopathy NGS Panel
- 132. SYMPHONY™ Personalized Breast Cancer Genomic Profile
- 133. TAADNext
- 134. Target Now™ molecular profiling test (aka MI Profile, MI Profile X)
- 135. TargetPrint®
- 136. TheraPrint®
- 137. theraSEEK Sequence Analysis for Functional Disorders
- 138. Thrombocytopenia NextGen Sequencing (NGS) Panel
- 139. TruGenome Undiagnosed Disease Test

- 140. TruGenome Technical Sequence Data (whole exome sequencing test for labs and physicians who will make their own clinical interpretations make their own clinical interpretations)
- 141. Universal Carrier Panel
- 142. Vectra DA (Covered for [Medicare](#) members only)
- 143. Vitreoretinopathy NGS Panel
- 144. Xpresys Lung (Covered for [Medicare](#) members only)

Revision History

Mar. 8, 2019	Added Oncotype DCIS, Oncotype DX AR-V7 Nucleus and Xpresys Lung tests for Medicare members
Feb. 8, 2018	Added Clonoseq® for Medicare members Added link to MYvantage® Hereditary Comprehensive Cancer Panel Medical Guideline and removed MYvantage from Limitations/Exclusions
Oct. 12, 2018	Removed Corus® CAD Medicare coverage effective Dec. 12. 2018
Aug. 8, 2018	Added Medicare coverage of Guardant360® Pervenio™ Lung NGS
May 5, 2018	Added Commercial and Medicaid coverage of the Decipher, Oncotype, Prolaris and ProMark gene/biomarker expression profiling tests for prostate cancer to pre-existing Medicare coverage
Apr. 13, 2018	Added FoundationOne CDx test coverage for Medicare members Removed the following test, Thyroid, FNA Cytomorphology with Molecular tests (Quest), from the list of covered tests for thyroid lesions with indeterminate cytology (no longer available from Quest) Added language communicating noncoverage of testing to confirm results of consumer-based testing Added language clarifying that whole exome and whole genome sequencing is considered investigational Updated list of lab tests regarded as investigational
Apr. 14, 2017	Added ThyraMIR Thyroid miRNA classifier to list of eligible tests for thyroid lesions with indeterminate cytology Added Melaris to investigational list
Feb. 2, 2017	Added the following tests to investigational list: Oncofocus®, Previstage™
Sept. 9, 2016	Added the following tests to investigational list: DecodEX, Oncovue, OvaNext™, Panexia®
Aug. 12, 2016	Added Medicare coverage for CancerTYPE ID®. Added the following tests to investigational list: Brevagen/Brevagenplus, My5-FU™ (previously OnDose™), OncoVantage™, OPA 1 gene sequencing for autosomal dominant optic atrophy and/or optic neuropathy, Proove Opioid Risk Test
Jul. 8, 2016	Added the following tests to investigational list: Combined Cardiac Panel, Counsyl preconception carrier genetic screening, miReview®, Myeloid Molecular Profile, Paradigm Cancer Diagnostics [PCDx] Test, Pediatric Neurology Region of Interest Trio, Progenity® Pan-Ethnic Carrier Screening Panel, Rotterdam Signature, Saethre-Chotzen Syndrome (TWIST) Sequencing and MLPA, SelectMDx for prostate cancer
5/13/2016	Added Medicare coverage for Prosigna™ Breast Cancer Prognostic Gene Signature Assay. Added GeneStrat and Molecular Intelligence to list of investigational tests. Reinstated coverage of the following tests for Medicare members: Corus® CAD, ConfirmMDx™, Decipher® Prostate Classifier, Oncotype DX® Colon, Oncotype DX® prostate, Prolaris® and ResponseDX Tissue Origin Test

4/8/2016	Tests no longer covered for Medicare members (NGS Medicare Molecular Pathology LCD effective 4/1/2016) — Corus [®] CAD, ConfirmMDx [™] , Decipher [®] Prostate Classifier, Oncotype DX [®] colon, Oncotype DX [®] prostate, Prolaris [®] and ResponseDX Tissue Origin Test. Non-covered tests added to investigational list — GeneFx [®] Colon, myPath [®] (NGS Medicare Molecular Pathology LCD effective 4/1/2016)
12/21/2015	Amended Limitations/Exclusions Section to reflect positive Medicare coverage for Oncotype Prostate.
10/9/2015	Amended Limitations/Exclusions Section to reflect positive Medicare coverage for Decipher Prostate Classifier and Prolaris

References

- AHRQ. Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin. February 2013. <http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf>. Accessed February 15, 2019.
- Centers for Medicare & Medicaid Services. Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. March 2018. <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=290&bc=AAAAAAAAACAA&>. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Colon Cancer. Version 4.2018. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Cutaneous Melanoma. Version 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 2.2019. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/cli.pdf. February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2019. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Occult Primary (Cancer of Unknown Primary [CUP]). Version 2.2019. http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed February 15, 2019.
- National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology. Prostate Cancer Version 4.2018. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed February 15, 2019.
- National Government Services. Local Coverage Determination (LCD): Molecular Pathology Procedures. Jan. 2019. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35000&ver=128&Date=&DocID=L35000&bc=iAAAABABAAAA&>. Accessed February 15, 2019.
- National Government Services. Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Non-Small Cell Lung Cancer. April 2016. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36376&ver=3&DocType=All&bc=AAIAAAAAAAAA&>. Accessed February 15, 2019.
- Noridian. Local Coverage Determination (LCD): MolDX: ConfirmMDx Epigenetic Molecular Assay. February 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35632>. Accessed February 15, 2019.
- Novitas Solutions. Local Coverage Determination (LCD): Biomarkers for Oncology. January 2019. https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35396&ver=148&name=314*1&UpdatePeriod=711&bc=AQAAEAABAAAA&. Accessed February 15, 2019.
- Palmetto GBA. MolDX: Corus[®] CAD Assay. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37612&ver=4&DocType=Future&bc=AAIAAAAAAAAA&>. Nov. 2018. Accessed February 15, 2019.
- Palmetto GBA. MolDX-CDD: Decipher[®] Prostate Cancer Classifier Assay. April 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35868>. Accessed February 15, 2019.
- Palmetto. MolDX-CDD: Genomic Health[™] Oncotype DX[®] Prostate Cancer Assay. February 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd->

https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36153&ver=42&CntrctrSelected=381*1&Cntrctr=381&name=&DocType=Active&s=34%7c48%7c53%7c58&bc=AggAAAIBAAAA&. Accessed February 15, 2019.

Palmetto. MoIDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC). August 2018. [https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37699&ver=5&Cntrctr=240&name=+\(15201%2c+MAC++Part+A\)&DocType=Future&CntrctrSelected=240*1&s=50&LCntrctr=All&bc=AgIAAABAAAA&](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37699&ver=5&Cntrctr=240&name=+(15201%2c+MAC++Part+A)&DocType=Future&CntrctrSelected=240*1&s=50&LCntrctr=All&bc=AgIAAABAAAA&). Accessed August 17, 2018.

Palmetto GBA. MoIDX-CDD: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease. February 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37043>. Accessed February 15, 2019.

Palmetto GBA. MoIDX-CDD: ProMark Risk Score. February 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36665>. Accessed February 15, 2019.

Palmetto GBA. MoIDX: Oncotype DX DX® Breast Cancer for DCIS. July 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36941&ver=13&SearchType=Advanced&CoverageSelection=Local&ArticleType=SAD%7cEd&PolicyType=Both&s=All&Keyword=oncotype&KeywordLookUp=Title&KeywordSearchType=Exact&kq=true&bc=IAAAACAAAA&>. Accessed March 22, 2019.

Palmetto GBA. MoIDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer. December 2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37701&ver=3&SearchType=Advanced&CoverageSelection=Local&ArticleType=SAD%7cEd&PolicyType=Both&s=All&Keyword=oncotype&KeywordLookUp=Title&KeywordSearchType=Exact&kq=true&bc=IAAAACAAAA&>. Accessed March 22, 2019.

Noridian Healthcare Solutions. MoIDX: Xpresys Lung. September 2017. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37054&ver=5&DocType=1&bc=AAIAAAAAAAAA&>. Accessed March 22, 2019.

Specialty-matched clinical peer review.